Non-Peptide Small Molecule FGF14:Nav1.6 Channel Complex Protein-Protein Interaction Modulators
AssigneeBoard of Regents, The University of Texas System
InventorsJia Zhou, Fernanda Laezza, Pingyuan Wang, Nolan M. Dvorak, Paul A. Wadsworth
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel small molecule FGF14:NAV1.6 channel complex protein-protein interaction modulators of the general structure according to Formula (I), and the preparation and use thereof:
Claims34
A compound of Formula I or a pharmaceutically acceptable salt thereof, wherein:
- R1 is H, alkyl, alkoxy, halogen, cyano, amino, hydroxyl, NO2, CF3 or —OCF3;
- A is an aryl ring or a heteroaryl ring (e.g., pyridine), wherein ring A is fused to the C4 and C5 of the 5-membered N-heterocycle ring moiety of Formula I, e.g., as shown the compounds exemplified below;
- R2 is H, alkyl, alkoxy, halogen, —CO2R10, —CO2Me or hydroxyl;
- R3 is H, alkyl, alkoxy, halogen or hydroxyl;
- or R2 and R3 together form a 3-6 membered cycloalkyl ring;
- R4 is H, alkyl, alkoxy, halogen, cyano, hydroxyl or NT1T2;
- T1 is H, alkyl;
- T2 is independently chosen from:
- H, alkyl, cycloalkyl, benzyl, allyl, hydroxyl-alkyl;
- or T1 and T2 together form a 4-12 membered cycloalkyl ring or cycloheteroalkyl ring, wherein the 4-12 membered cycloalkyl ring or cycloheteroalkyl ring is optionally substituted with one or more groups selected independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, benzyl, alkoxy, halogen, cyan, nitro, amino, hydroxyl, CHF2, CF3 or —OCF3;
- n=0, 1, 2, 3, or 4;
- R5 is H, alkyl, aryl, cycloalkyl (e.g., is a bridged 6-14-membered bicyclic cycloalkyl, with 1-3 carbon length “bridge”);
- or heteroaryl, wherein each ring is optionally substituted with one or more groups selected independently from:
- H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, benzyl, alkoxy (e.g., OMe, 3-OMe), halogen, cyano (e.g., 3-CN), nitro, amino, amido (e.g., 3-amido hydroxyl, —COOR8 (e.g., —COOMe), —CONHR9, CHF2, CF3 or —OCF3, wherein alkyl is optionally substituted with one or more substituents chosen from:
- hydroxyl, cyan, amino, or halogen;
- R6, and R7 are independently chosen from H, alkyl, F, CHF2, CF3, etc., or R6 and R7 taken together form a 3-7 membered ring (e.g., cyclopropane);
- R8 is independently chosen from:
- H, alkyl, aryl, cycloalkyl, benzyl;
- and
- R9 is independently chosen from:
- H, alkyl, aryl, cycloalkyl, benzyl, or substituted benzyl.
- R10 is alkyl (e.g., C1-C6-alkyl), aryl, or alkylaryl.
(canceled)
(canceled)
(canceled)
(canceled)
A compound of the Formula (II) or a pharmaceutically acceptable salt thereof, wherein:
- R4 is hydroxyl or NT1T2;
- wherein T1 is H or alkyl;
- and wherein T2 is independently chosen from H, alkyl, cycloalkyl, benzyl, allyl, hydroxyl-alkyl;
- or T1 and T2 together form a 4-12 membered cycloalkyl ring or cycloheteroalkyl ring, wherein the 4-12 membered cycloalkyl ring is optionally substituted with one or more groups selected independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, benzyl, alkoxy, halogen, cyan, nitro, amino, hydroxyl, CHF2, CF3 or —OCF3;
- R5 is an aryl ring or a cycloalkyl ring, wherein each ring is optionally substituted with one or more groups selected independently from:
- H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, benzyl, alkoxy, halogen, cyano, nitro, amino, hydroxyl, —COOR8, —CONR9, CHF2, CF3 or —OCF3, wherein alkyl is optionally substituted with one or more chosen substituents chosen from:
- hydroxyl, cyano, amino, or halogen;
- R8 is independently chosen from:
- H, alkyl, aryl, cycloalkyl, or benzyl;
- and
- R8 is independently chosen from:
- H, alkyl, aryl, cycloalkyl, benzyl, or substituted benzyl.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein:
- wherein R1, R4, and R5 are defined as for the compound of Formula I.
The compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein:
- wherein R1 and R5 are defined as for the compound of Formula I.
(canceled)
(canceled)
(canceled)
A method of treating a disease or condition in a patient comprising administering to the patient a therapeutically effective amount of a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.